Halberd Corporation (OTC: HALB) Signs Worldwide Agreement for Medications & Nutraceuticals

Halberd Corporation (OTC: HALB) signed a contract with “The Hamden Group” with extensive experience in the sales and marketing of pharmaceutical products. The Hamden will market, sell, and distribute HALB’s patented low-dose Naltrexone medication, and the HALB proprietary Vita-Shield-Max TM Nutraceutical Product worldwide.

Market Action

On Monday, HALB stock went up 1.79% to $0.0114 with 447K shares, compared to its average volume of 961K shares. The stock moved within a range of $0.0092 – 0.0114 after opening trade at $0.0112.

On Monday it emerged that Halberd Corporation had inked a contract with the firm Hamden Group. It could be a good idea for investors to take a closer look at the development ahead of today’s trading. Hamden Group was established not too long ago and is made up of Croden family members and Darren Hamans. It should be noted that Darren Hamans is an experienced professional in the field of pharmaceutical marketing and sales.

Darren Hamans is also the Business Development consultant at Halberd and is credited for having established the Hamden Group for the distribution and sales of therapeutics produced by Halberd. By way of this agreement, Hamden will now have the exclusive global rights to distribute, sell and market Vita-Shield-Max TM Nutraceutical product and the low-dose Naltrexone medicine from Halberd.

The exact specifics of the deal are going to be announced soon by the companies. Darren Hamans, who is the Chief Executive Officer of Hamden Group, noted that it had been created for the purpose of boosting the revenues of Halberd Corporation substantially. The President and Chief Executive Officer of Halberd Corporation, William A Hartman spoke about the development as well.

He called it a major milestone for Halberd since the deal could potentially boost the revenues generated from the products that are going to be sold by Hamden Group. He went on to add the potential sales of the products could be huge. It remains to be seen whether the Halberd stock gets any attention from investors.

Traders Note

HALB stock is trading above the 20-Day and 50-Day Moving averages of $0.0114 and $0.0108 respectively. However, the stock is trading below the 200-Day moving average of $0.0156. The stock is up 35% over the past month.

Related posts:

Human Unitec International, Inc. (OTCMKTS:HMNU) Announces Medical Equipment Deal in China Closed Up 17.78% 10x Volume: RSHN, ALST, HALB, EPAZ Pennies @ 52-Week Lows Time to Buy: ZRFY, HALB, MMMW, ALST, HMNU, CEOS 2023 Medical Stocks to Watch Under 1¢ Now! HALB, GRST, HMNU Halberd (OTC:HALB) Eradicates 99.5% of CDC Provided Antibiotic Resistant Bacteria Halberd Corp (OTC:HALB) & Centers of Disease Control (CDC) to Discuss Results at Youngstown State University (YSU)